Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3532294 | 1.00 | ALDH1A1 (0.51) | ALDH1A1MAPTKDM4EMEN1TP53 | |
| Methyl 3-(2,4-Dichlorophenyl)Acrylate SCHEMBL6315070 | 0.87 | MAPT (0.62) | ALDH1A1MAPTKDM4EMEN1TP53 | |
| Methyl 3-(2,4-Dichlorophenyl)Acrylate SCHEMBL7434845 | 0.87 | MAPT (0.62) | ALDH1A1MAPTKDM4EMEN1TP53 | |
| SCHEMBL14926720 | 0.85 | MAPT (0.50) | ALDH1A1MAPTKDM4EMEN1TP53 | |
| SCHEMBL1745374 | 0.85 | BACE1 (0.69) | ALDH1A1MAPTKDM4EMEN1TP53 | |
| SCHEMBL8267197 | 0.84 | MAPT (0.49) | ALDH1A1MAPTKDM4EMEN1TP53 | |
| SCHEMBL27852162 | 0.84 | MAPT (0.49) | ALDH1A1MAPTKDM4EMEN1TP53 | |
| SCHEMBL28647046 | 0.80 | MAPT (0.46) | ALDH1A1MAPTKDM4EMEN1TP53 | |
| SCHEMBL5707175 | 0.79 | MAOB (0.69) | ALDH1A1MAPTKDM4EMEN1HPGD | |
| SCHEMBL2152903 | 0.79 | MAOB (0.69) | ALDH1A1MAPTKDM4EMEN1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816385-B2 | Dimeric dicarboxylic acid derivatives, their preparation and use | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-10-19 | — | — | US | disclosed |
| EP-1578716-A1 | DICARBOXYLIC ACID DERIVATIVES AS PPAR-AGONISTS | NOVO NORDISK A/S (DK) | 2005-09-28 | — | — | EP | disclosed |
| US-20040259950-A1 | Novel compounds, their preparation and use | HIGH POINT PHARMACEUTICALS, LLC | 2004-12-23 | — | — | US | disclosed |
| WO-2004056740-A1 | DICARBOXYLIC ACID DERIVATIVES AS PPAR-AGONISTS | NOVO NORDISK A/S (DK) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259950-A1 | Novel compounds, their preparation and use | PPARG, PPARA, PPARD | ALDH1A1 926/4885MAPT 3047/4885KDM4E 3030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.